{"id":5137,"date":"2024-04-09T00:56:40","date_gmt":"2024-04-08T16:56:40","guid":{"rendered":"https:\/\/flcube.com\/?p=5137"},"modified":"2025-01-06T18:15:10","modified_gmt":"2025-01-06T10:15:10","slug":"beigene-launches-guangzhou-adc-production-park-to-strengthen-manufacturing-muscle","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=5137","title":{"rendered":"BeiGene Launches Guangzhou ADC Production Park to Strengthen Manufacturing Muscle"},"content":{"rendered":"\n

BeiGene (NASDAQ: BGNE<\/a>; HKG: 6160<\/a>; SHA: 688235<\/a><\/a>), a leading biopharmaceutical company, has announced the operational launch of its antibody drug conjugate (ADC) production park in Guangzhou, a strategic move to bolster the company’s clinical and commercial manufacturing capabilities. The new facility is expected to significantly enhance the production of BeiGene’s pipeline candidates, with a first-phase capacity of 64,000 liters, positioning the company to meet the growing demand for innovative drugs in the global market .<\/p>\n\n\n\n

The ADC production park has been constructed to meet the highest biopharmaceutical industry standards, ensuring the efficiency, safety, and controllable quality of ADC drugs throughout the research and production process. The facility’s advanced production equipment, state-of-the-art R&D facilities, and operation management systems will play a crucial role in maintaining the quality and efficacy of BeiGene’s ADC therapies .<\/p>\n\n\n\n

BeiGene’s commitment to advancing ADC therapies is further underscored by its recent licensing and partnership deals. In 2018, the company signed a deal with Zymeworks for two HER2-targeted candidates, marking a significant step in expanding its ADC pipeline. In November 2019, BeiGene entered into a deal with Seattle Genetics, securing rights to a preclinical ADC for markets outside the Americas, Europe, and Japan, valued at up to USD 160 million. Most notably, in July 2023, BeiGene inked a deal with Duality Bio for a preclinical ADC candidate, with a potential value of up to USD 1.3 billion, further solidifying its position as a major player in the global ADC field \u3002<\/p>\n\n\n\n

The commencement of operations at the Guangzhou ADC production park not only signifies BeiGene’s continued growth but also its dedication to bringing transformative medicines to patients worldwide. With reserved space for future expansion, the facility is poised to double its current production capacity, ensuring that BeiGene can fully meet the market’s demand for innovative drugs and continue to be at the forefront of ADC development and manufacturing .- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading biopharmaceutical company, has announced the operational…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[35,185,2092,847,846,3046,848],"class_list":["post-5137","post","type-post","status-publish","format-standard","hentry","category-company","tag-adc-xdc","tag-beigene","tag-beone-medicines","tag-hkg-6160","tag-nasdaq-bgne","tag-nasdaq-onc","tag-sha-688235"],"yoast_head":"\nBeiGene Launches Guangzhou ADC Production Park to Strengthen Manufacturing Muscle - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"BeiGene (NASDAQ: BGNE), a leading biopharmaceutical company, has announced the operational launch of its antibody drug conjugate (ADC) production park in Guangzhou, a strategic move to bolster the company's clinical and commercial manufacturing capabilities. The new facility is expected to significantly enhance the production of BeiGene's pipeline candidates, with a first-phase capacity of 64,000 liters, positioning the company to meet the growing demand for innovative drugs in the global market .\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=5137\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeiGene Launches Guangzhou ADC Production Park to Strengthen Manufacturing Muscle\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=5137\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-08T16:56:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-06T10:15:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5137#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5137\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BeiGene Launches Guangzhou ADC Production Park to Strengthen Manufacturing Muscle\",\"datePublished\":\"2024-04-08T16:56:40+00:00\",\"dateModified\":\"2025-01-06T10:15:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5137\"},\"wordCount\":323,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"BeiGene\",\"BeOne Medicines\",\"HKG: 6160\",\"NASDAQ: BGNE\",\"NASDAQ: ONC\",\"SHA: 688235\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=5137#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5137\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=5137\",\"name\":\"BeiGene Launches Guangzhou ADC Production Park to Strengthen Manufacturing Muscle - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-04-08T16:56:40+00:00\",\"dateModified\":\"2025-01-06T10:15:10+00:00\",\"description\":\"BeiGene (NASDAQ: BGNE), a leading biopharmaceutical company, has announced the operational launch of its antibody drug conjugate (ADC) production park in Guangzhou, a strategic move to bolster the company's clinical and commercial manufacturing capabilities. The new facility is expected to significantly enhance the production of BeiGene's pipeline candidates, with a first-phase capacity of 64,000 liters, positioning the company to meet the growing demand for innovative drugs in the global market .\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5137#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=5137\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5137#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeiGene Launches Guangzhou ADC Production Park to Strengthen Manufacturing Muscle\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BeiGene Launches Guangzhou ADC Production Park to Strengthen Manufacturing Muscle - Insight, China's Pharmaceutical Industry","description":"BeiGene (NASDAQ: BGNE), a leading biopharmaceutical company, has announced the operational launch of its antibody drug conjugate (ADC) production park in Guangzhou, a strategic move to bolster the company's clinical and commercial manufacturing capabilities. The new facility is expected to significantly enhance the production of BeiGene's pipeline candidates, with a first-phase capacity of 64,000 liters, positioning the company to meet the growing demand for innovative drugs in the global market .","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=5137","og_locale":"en_US","og_type":"article","og_title":"BeiGene Launches Guangzhou ADC Production Park to Strengthen Manufacturing Muscle","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=5137","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-04-08T16:56:40+00:00","article_modified_time":"2025-01-06T10:15:10+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=5137#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=5137"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BeiGene Launches Guangzhou ADC Production Park to Strengthen Manufacturing Muscle","datePublished":"2024-04-08T16:56:40+00:00","dateModified":"2025-01-06T10:15:10+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=5137"},"wordCount":323,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","BeiGene","BeOne Medicines","HKG: 6160","NASDAQ: BGNE","NASDAQ: ONC","SHA: 688235"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=5137#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=5137","url":"https:\/\/flcube.com\/?p=5137","name":"BeiGene Launches Guangzhou ADC Production Park to Strengthen Manufacturing Muscle - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-04-08T16:56:40+00:00","dateModified":"2025-01-06T10:15:10+00:00","description":"BeiGene (NASDAQ: BGNE), a leading biopharmaceutical company, has announced the operational launch of its antibody drug conjugate (ADC) production park in Guangzhou, a strategic move to bolster the company's clinical and commercial manufacturing capabilities. The new facility is expected to significantly enhance the production of BeiGene's pipeline candidates, with a first-phase capacity of 64,000 liters, positioning the company to meet the growing demand for innovative drugs in the global market .","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=5137#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=5137"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=5137#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BeiGene Launches Guangzhou ADC Production Park to Strengthen Manufacturing Muscle"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/5137","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5137"}],"version-history":[{"count":3,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/5137\/revisions"}],"predecessor-version":[{"id":6033,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/5137\/revisions\/6033"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5137"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5137"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5137"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}